WHAT IS CLAIMED IS:

1. Use of an ophthalmological composition in the manufacture of a medicament for the treatment of allergies, wherein said ophthalmological composition comprises from about 0.005% to about 0.050% brimonidine and an effective amount of a histamine antagonist, wherein w/v denotes weight by total volume of the composition.

2. The use of claim 1, wherein the histamine antagonist is selected from the group consisting of naphazoline, antazoline, azelastine, carbinoxamine, cyproheptadine, emedastine, hydroxyzine, levocabastine, brompheniramine, chlorpheniramine, clemastine, diphenhydramine, ketotifen, loratadine, desloratadine, cetirizine, fexofenadine, olopatadine, acrivastine, ebastine, norastemizole, levocetirizine, mizolastine, pheniramine, pharmaceutically acceptable salts thereof and combinations thereof.

3. The use of claim 1, wherein the histamine antagonist is at a concentration from about 0.025% to about 0.7% w/v.

4. The use of claim 1, wherein the ophthalmological composition further comprises a nonionic surfactant, hydroxypropylmethyl cellulose, a buffer and optionally, sorbate.

5. Use of the composition of claim 1 in the manufacture of a medicament for treating or preventing an allergic response in a subject in need thereof.

6. Use of an ophthalmological composition in the manufacture of a medicament for the treatment of glaucoma, wherein said ophthalmological composition comprises from about 0.01% to about 0.050% w/v brimonidine and an effective amount of a second glaucoma drug, wherein w/v denotes weight by total volume of the composition.

7. The use of claim 6, wherein the second glaucoma drug is selected from the group consisting of a prostaglandin, a beta-blocker, a rho kinase inhibitor, and a carbonic anhydrase inhibitor.

8. The use of claim 6, wherein the second glaucoma drug is selected from the group consisting of latanoprost, bimatoprost, travaprost, tafluprost, netarsudil, carteolol, timoptic, timolol, betaloxol, levobunolol, metipranolol, brinzolamide, dorzolamide, acetazolamide, methazolamide and pharmaceutically acceptable salts thereof.

9. The use of claim 7, wherein the second glaucoma drug is a prostaglandin at a concentration from about 0.001% to about 0.1% w/v or a rho kinase inhibitor at a concentration from about 0.01% to about 1.0% w/v or a beta-blocker at a concentration from about 0.1% to about 1.0% w/v or a carbonic anhydrase inhibitor at a concentration from about 0.5% to about 5% w/v.

10. The use of claim 6, wherein brimonidine is at a concentration of about 0.050% w/v and the second glaucoma drug is latanoprost at a concentration of about 0.005% w/v.

11. The use of claim 6, wherein said ophthalmological composition further comprises a nonionic surfactant, a viscosity enhancer, a buffer and optionally, sorbate.

12. Use of the composition as defined in claim 6 in the manufacture of a medicament for the treatment of glaucoma in a subject in need thereof.

13. Use of an ophthalmological composition in the manufacture of a medicament for reducing of inflammation comprising from about 0.005% to about 0.050% w/v brimonidine and an effective amount of a nonsteroidal anti-inflammatory drug (NSAID), wherein w/v denotes weight by total volume of the composition.

14. The use of claim 13, wherein the NSAID is selected from the group consisting of ketorolac, aspirin, celecoxib, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, oxaprozin, salsalate, sulindac, tolmetin and pharmaceutically acceptable salts thereof and combinations thereof.

15. The use of claim 14, wherein the NSAID is ketorolac.

16. The use of claim 13, wherein said ophthalmological composition further comprises a nonionic surfactant, a viscosity enhancer, a buffer and optionally, sorbate.

17. The use of claim 16, wherein the nonionic surfactant is a polysorbate at a concentration from about 1% to about 5% w/v.

18. Use of the composition as defined in claim 13 in the manufacture of a medicament for reducing inflammation in a subject in need thereof.

19. A composition for the treatment of glaucoma comprising:

about 0.001% w/v latanoprost or 0.05% w/v timolol;

about 0.050% w/v brimonidine;

about 2.5% w/v polysorbate;

about 1.2% w/v hydroxypropylmethyl cellulose;

about 5 millimolar boric acid; and

optionally, about 0.1% w/v sorbate,

wherein the composition has a pH of about 7.4.

20. A composition for the treatment of allergic conjunctivitis comprising:

about 0.0035% w/v ketotifen fumarate;

about 0.035% w/v brimonidine;

about 2.5% w/v polysorbate;

from about 0.1% to about 1.2% w/v hydroxypropylmethyl cellulose;

about 4 millimolar citrate buffer; and

optionally, about 0.1% w/v sorbate,

wherein the composition has a pH of about 6.5.